Edition:
United States

Halozyme Therapeutics Inc (HALO.A)

HALO.A on American Stock Exchange

16.42USD
19 Sep 2017
Change (% chg)

$-0.28 (-1.68%)
Prev Close
$16.70
Open
$17.10
Day's High
$17.10
Day's Low
$16.31
Volume
492
Avg. Vol
--
52-wk High
$17.10
52-wk Low
$11.58

Select another date:

Thu, Sep 14 2017

Photo

Halozyme to license drug delivery tech to Roche, Bristol-Myers

U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations.

BRIEF-Halozyme licenses new Enhanze target for $30 mln upfront payment

* Halozyme licenses new enhanze target for $30 million upfront payment, future milestones and royalties

Halozyme to license drug delivery tech to Roche, Bristol-Myers

Sept 14 U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations.

BRIEF-Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology

* Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology

BRIEF-Halozyme reports Q2 loss per share $0.23

* Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S

BRIEF-Halozyme announces initiation of clinical trial collaboration

* Initiation of clinical trial collaboration evaluating Halozyme's pegph20 in combination with anti-PDL1 immunotherapy

BRIEF-Halozyme Therapeutics, unit entered into first amendment to amended, restated lease with BMR-11388 Sorrento Valley Road

* Halozyme Therapeutics Inc - co, unit entered into a first amendment to amended and restated lease with bmr-11388 sorrento valley road lp

BRIEF-Halozyme phase 2 data in advanced pancreas cancer presented

* Halozyme phase 2 data in advanced pancreas cancer presented at european society for medical oncology symposium

BRIEF-Halozyme Therapeutics prices public offering of common stock

* Halozyme Therapeutics prices public offering of common stock

BRIEF-Halozyme Therapeutics announces public offering of common stock

* Halozyme Therapeutics announces public offering of common stock

Select another date: